Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LC-MS/MS identification of MAVS-interacting proteins

ABSTRACT: The nanoLC-MS/MS experiments were performed on a Q Exactive mass spectrometer (Thermo Scientific) in data-dependent mode, which allowed MS data acquisition at a high resolution of 70,000 (m/z 200) across an m/z range of 300–1600. The raw data from Q Exactive analysis were analyzed with Proteome Discovery version 1.4 using the Sequest HT search engine for protein identification and Percolator for false discovery rate (FDR) analysis. The data were searched against the UniProt human protein database (updated on 06-2013). FDR analysis was performed with Percolator, and FDR < 1% was set as the threshold for protein identification.

ORGANISM(S): Homo Sapiens

SUBMITTER: Weiqi Zhang

PROVIDER: PXD041140 | iProX | Mon Mar 27 00:00:00 BST 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

MAVS Antagonizes Human Stem Cell Senescence as a Mitochondrial Stabilizer.

Wang Cui C Yang Kuan K Liu Xiaoqian X Wang Si S Song Moshi M Belmonte Juan Carlos Izpisua JCI Qu Jing J Liu Guang-Hui GH Zhang Weiqi W

Research (Washington, D.C.) 20230727

Mitochondrial dysfunction is a hallmark feature of cellular senescence and organ aging. Here, we asked whether the mitochondrial antiviral signaling protein (MAVS), which is essential for driving antiviral response, also regulates human stem cell senescence. To answer this question, we used CRISPR/Cas9-mediated gene editing and directed differentiation techniques to generate various MAVS-knockout human stem cell models. We found that human mesenchymal stem cells (hMSCs) were sensitive to MAVS de ...[more]

PMID: 37521327

Similar Datasets

longitudinal expression profiling in whole blood of multiple sclerosis patients and controls [MS vs Ctrl Discovery dataset]

Project description:Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. In total, 626 Affymetrix exon arrays were analyzed, split into discovery and replication data sets. This metadata file contains information on all samples processed in the discovery data set (n=212) when we compared gene expression in untreated MS patients (n=62) to healthy controls (n=41). The following comparisons were made: untreated MS vs Controls (discovery and replication), untreated vs Interferon treated MS (discovery and replication). For each comparison, respective arrays were processed (background corrected and normalized) together, but seperate from other comparisons. The two time points for controls were averaged. For the first comparison, we report differentially expressed genes at an FDR cutoff of 0.1 at any of the three tested time points in MS patients in the discovery data set. For the second comparison, the FDR cutoff was 0.001. The respective genes were validated in the replication data set when they passed a nominal p-value cutoff of 0.05 at any of the three tested time points.

2013-06-17 | E-GEOD-41848 | biostudies-arrayexpress

longitudinal expression profiling in whole blood of multiple sclerosis patients and controls [MS vs Ctrl Replication dataset]

Project description:Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. In total, 626 Affymetrix exon arrays were analyzed, split into discovery and replication data sets. This metadata file contains information on all samples processed in the replication data set (n=102) when we compared gene expression in untreated MS patients (n=27) to healthy controls (n=25). The following comparisons were made: untreated MS vs Controls (discovery and replication), untreated vs Interferon treated MS (discovery and replication). For each comparison, respective arrays were processed (background corrected and normalized) together, but seperate from other comparisons. The two time points for controls were averaged. For the first comparison, we report differentially expressed genes at an FDR cutoff of 0.1 at any of the three tested time points in MS patients in the discovery data set. For the second comparison, the FDR cutoff was 0.001. The respective genes were validated in the replication data set when they passed a nominal p-value cutoff of 0.05 at any of the three tested time points.

2013-06-17 | E-GEOD-41849 | biostudies-arrayexpress

Glomus sp. MS strain:MS

Project description:Glomus sp. MS strain:MS Genome sequencing

| PRJNA210520 | ENA

longitudinal expression profiling in whole blood of multiple sclerosis patients and controls [IFN_discovery dataset]

Project description:Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. In total, 626 Affymetrix exon arrays were analyzed, split into discovery and replication data sets. This metadata file contains information on all samples processed in the discovery data set (n=318) when we compared gene expression in untreated MS patients (n=62) to IFN treated patients (n=58). The following comparisons were made: untreated MS vs Controls (discovery and replication), untreated vs Interferon treated MS (discovery and replication). For each comparison, respective arrays were processed (background corrected and normalized) together, but seperate from other comparisons. The two time points for controls were averaged. For the first comparison, we report differentially expressed genes at an FDR cutoff of 0.1 at any of the three tested time points in MS patients in the discovery data set. For the second comparison, the FDR cutoff was 0.001. The respective genes were validated in the replication data set when they passed a nominal p-value cutoff of 0.05 at any of the three tested time points.

2013-06-17 | E-GEOD-41846 | biostudies-arrayexpress

Methanosarcina barkeri MS strain:MS

Project description:Methanosarcina barkeri MS strain:MS Raw sequence reads

| PRJNA613292 | ENA

longitudinal expression profiling in whole blood of multiple sclerosis patients and controls [IFN_replication dataset]

Project description:Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. In total, 626 Affymetrix exon arrays were analyzed, split into discovery and replication data sets. This metadata file contains information on all samples processed in the replication data set (n=183) when we compared gene expression in untreated MS patients (n=27) to IFN treated patients (n=48). The following comparisons were made: untreated MS vs Controls (discovery and replication), untreated vs Interferon treated MS (discovery and replication). For each comparison, respective arrays were processed (background corrected and normalized) together, but seperate from other comparisons. The two time points for controls were averaged. For the first comparison, we report differentially expressed genes at an FDR cutoff of 0.1 at any of the three tested time points in MS patients in the discovery data set. For the second comparison, the FDR cutoff was 0.001. The respective genes were validated in the replication data set when they passed a nominal p-value cutoff of 0.05 at any of the three tested time points.

2013-06-17 | E-GEOD-41847 | biostudies-arrayexpress

longitudinal expression profiling in whole blood of multiple sclerosis patients and controls [MS vs Ctrl Discovery dataset]

2013-06-17 | GSE41848 | GEO

FDR-controlled metabolite annotation for high-resolution imaging mass spectrometry imaging MS (LC-MS assay)

Project description:High-mass-resolution imaging mass spectrometry promises to localize hundreds of metabolites directly from tissues, cell cultures, and agar plates with cellular resolution, but is hampered by the lack of bioinformatics for automated metabolite identification. We developed the first bioinformatics framework for False Discovery Rate (FDR)-controlled metabolite annotation for high-mass-resolution imaging mass spectrometry (https://github.com/alexandrovteam/pySM) introducing a Metabolite-Signal Match (MSM) score and a target-decoy FDR-estimate for spatial metabolomics. LC-MS(/MS) datasets acquired from wild type adult mouse brain were used for the development of spatial metabolomics annotation bioinformatics. This study together with MTBLS317 and MTBLS378 provide the accompanying data for FDR-controlled metabolite annotation for high-resolution imaging mass spectrometry.

2016-12-05 | MTBLS378 | MetaboLights

Mouse splenocyte proteome - Proteome characterization of splenocytes from an Aβpp/ps-1 Alzheimer's disease model

Project description:Splenocytes from 14-month Alzheimer's Disease mouse model were separated with CD90.2 magetic beads into two cell subsets: CD90+ and CD90-. Proteome for these two subset were characterized with offline SCX-nanoLC-MS/MS. MS data was analyzed with Proteome Discoverer 1.3 software. MS/MS spectra were searched against the IPI mouse database (August 16, 2012, 59 534 sequences). SEQUEST search parameters were as follows: two maximum trypsin miscleavages; precursor and fragment mass tolerances of 10 ppm and 0.8 Da, respectively; carbamidomethyl modification on cysteine was a static modification; oxidation of methionine was a dynamic modification. Decoy database searching was employed to control the false discovery rate (FDR) and generate lists of peptides with high (FDR < 0.01) and medium (FDR < 0.05) confidence.

2014-01-31 | PXD000203 | Pride

PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration

Project description:An increasing amount of studies integrate mRNA sequencing data into MS-based proteomics to complement the translation product search space. We present the generation of a protein synthesis-based database from deep sequencing of ribosome-protected mRNA fragments. This approach increases the overall protein identification rates with 3% and 11% (improved and new identifications) for human and mouse respectively and enables proteome-wide detection of 5’-extended proteoforms, uORF translation and near-cognate translation start sites.

2014-12-01 | GSE58207 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data